CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE)
| Autor: | Christos Vaklavas, Mansoor N. Saleh, Andres Forero, Albert F. LoBuglio, Michael Yelin |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
business.industry
medicine.drug_class medicine.medical_treatment Cancer Monoclonal antibody medicine.disease Targeted therapy chemistry.chemical_compound chemistry Radioimmunotherapy Cancer cell Cancer research Medicine business Glembatumumab vedotin Triple-negative breast cancer Monoclonal antibody therapy |
| Zdroj: | Antibody-Drug Conjugates and Immunotoxins ISBN: 9781461454557 |
| Popis: | The development of monoclonal antibodies as cancer therapeutic agents has improved the outlook for many patients as evidenced by the number of such drugs that have been approved for oncologic indications [1]. Monoclonal antibodies allow selective killing of malignant cells (targeted therapy) with relative sparing of the normal tissues resulting in higher therapeutic efficacy and lower toxicity. The advances in the monoclonal antibody field have been expedited by the discovery of targets or pathways that are uniquely present or upregulated in cancer cells along with the advances in the technology used for the production of human or “humanized” reagents [2]. An additional strategy to enhance monoclonal antibody therapy is to utilize these reagents to selectively deliver radioisotopes (radioimmunotherapy) or cytotoxic agents (antibody–drug conjugates) to tumor cells [3, 4]. CDX-011 is a recently described antibody–drug conjugate in early clinical trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|